US5817491A
Expired / Lapsed
US
⏱️ 0.0 years remaining
VSV G pseusdotyped retroviral vectors
Assignee: Oxford Biomedica UK Ltd
•
Filing: 1994-12-22
•
Granted: 1998-10-06
•
Expires: 2014-12-22
Abstract
Abstract An enveloped vector particle contains gag and pol proteins from a retrovirus, a nucleic acid sequence and an envelope that includes VSV G envelope glycoprotein. The vector particle can be used to introduce nucleic acids into cells.
Inventors
- 👤 Jiing-Kuan Yee
- 👤 Nobuhiko Emi
- 👤 Theodore Friedmann
- 👤 Douglas J. Jolly
- 👤 Jack R. Barber
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 10:27
CPC Classifications
A; A01; A01K; A01K67/00; A01K67/027; A01K67/0275; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2013; A61K38/21; A61K38/217; A61K39/00; A61K39/0005; A61K48/00; C; C07; C07K; C07K14/00; C07K14/005; C07K14/435; C07K14/705; C07K14/70503; C07K14/70514; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/8509; C12N15/86; C12N15/87; C12N7/00; A01K2217/00; A01K2217/05; A01K2217/07; A01K2217/075; A61K35/00; A61K35/12; A61K35/13; C07K2319/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13022; C12N2740/13041; C12N2740/13043; C12N2740/13051; C12N2740/13052; C12N2740/13061; C12N2740/13062; C12N2740/15011; C12N2740/15022; C12N2740/16011; C12N2740/16211; C12N2740/16222
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
32 words
An enveloped vector particle comprising: gag and pol proteins from a retrovirus; a nucleic acid sequence associated with said vector particle; an envelope having vesicular stomatitis virus (VSV) G envelope glycoprotein therein.
Claim 2
Dependent Claim
32 words
An enveloped vector particle comprising: gag and pol proteins from a retrovirus; a nucleic acid sequence associated with said vector particle; an envelope having vesicular stomatitis virus (VSV) G envelope glycoprotein therein.
Claim 3
Dependent Claim
19 words
The vector particle of claim 1, wherein said gag and pol proteins are from the same species of retrovirus.
Claim 4
Dependent Claim
28 words
The vector particle of claim 2, wherein the nucleic acid sequence encodes a gene having an origin other than from said retrovirus, said gene being expressible into polypeptide.
Claim 5
Dependent Claim
14 words
The vector particle of claim 3, in which said polypeptide is a selectable marker.
Claim 6
Dependent Claim
17 words
The vector particle of claim 4, wherein the selectable marker is expressed by a neomycin resistance gene.
Claim 7
Dependent Claim
23 words
The vector particle of claim 3, wherein said nucleic acid sequence additionally comprises a promoter which can direct the transcription of said gene.
Claim 8
Dependent Claim
15 words
The vector particle of claim 2, wherein said gag and pol proteins are from MoMLV.
Claim 9
Dependent Claim
24 words
A method of introducing foreign nucleic acid into a cell, said method comprising infecting said cell with the enveloped vector particle of claim 1.
Claim 10
Dependent Claim
18 words
The method of claim 8, wherein said gag and pol proteins are from the same species of retrovirus.
Claim 11
Dependent Claim
17 words
The method of claim 9, wherein said cell is outside the normal host range of the retrovirus.
Claim 12
Dependent Claim
23 words
A method according to claim 9, wherein the retrovirus has a host range not including human cells or a subset of human cells.
Claim 13
Dependent Claim
11 words
A method according to claim 9, wherein the retrovirus is MoMLV.
Claim 14
Dependent Claim
41 words
A cell line that stably expresses or carries gag/pol, transfected or transduced with a nucleic acid molecule encoding a retroviral vector and a nucleic acid molecule encoding a VSV G protein, the cell line being capable of producing functional vector particles.
Claim 15
Dependent Claim
41 words
A cell line that stably expresses or carries gag/pol, transfected or transduced with a nucleic acid molecule encoding a retroviral vector and a nucleic acid molecule encoding a VSV G protein, the cell line being capable of producing functional vector particles.
Claim 16
Dependent Claim
13 words
The cell line of claim 13, wherein the cell line is transiently transfected.
Claim 17
Dependent Claim
6 words
A 293 cell stably expressing gag/pol.
Claim 18
Dependent Claim
6 words
A 293 cell stably expressing gag/pol.
Claim 19
Dependent Claim
13 words
The cell of claim 15, wherein the cell is a 293 2-3 cell.
Claim 20
Independent Claim
44 words
A method of making a VSV G pseudotyped virus, comprising: introducing into a cell line that stably expresses gag/pol a VSV G protein expression vector and a retroviral vector construct, the resulting cell line being capable of producing vector particles comprising VSV G protein.
Claim 21
Independent Claim
44 words
A method of making a VSV G pseudotyped virus, comprising: introducing into a cell line that stably expresses gag/pol a VSV G protein expression vector and a retroviral vector construct, the resulting cell line being capable of producing vector particles comprising VSV G protein.
Claim 22
Dependent Claim
20 words
The method of claim 17, wherein the retroviral vector construct is introduced prior to the VSV G protein expression vector.
Claim 23
Dependent Claim
27 words
The method of claim 18, wherein the method further comprises selecting for cells carrying the retroviral vector construct prior to introducing the VSV G protein expression vector.
Claim 24
Independent Claim
60 words
A method of making a VSV G pseudotyped virus, comprising: (a) cotransfecting or sequentially transfecting a cell with a vector that directs the expression of gag/pol and a retroviral vector construct; and (b) introducing a VSV G protein expression vector into the cotransfected or sequentially transfected cell, the resulting cell being capable of producing vector particles comprising VSV G protein.
Claim 25
Independent Claim
60 words
A method of making a VSV G pseudotyped virus, comprising: (a) cotransfecting or sequentially transfecting a cell with a vector that directs the expression of gag/pol and a retroviral vector construct; and (b) introducing a VSV G protein expression vector into the cotransfected or sequentially transfected cell, the resulting cell being capable of producing vector particles comprising VSV G protein.
Claim 26
Dependent Claim
27 words
The method of claim 20, wherein the cell is cotransfected, and the method includes selecting for transfected cells prior to introducing a VSV G protein expression vector.
Claim 27
Dependent Claim
26 words
The method of claim 20, wherein the cell is sequentially transfected, and the method include selecting for cells expressing either gag/pol or the retroviral vector construct.
References Cited (Backward Citations)
US4405712A
Cited
US4650764A
Cited
US4708818A
Cited
WO1986000922A1
Cited
EP0178220A2
Cited
US4725669A
Cited
US4980286A
Cited
US4868116A
Cited
US5081029A
Cited
EP0245136A1
Cited
EP0243204A2
Cited
US4861719A
Cited
EP0273782A1
Cited
US4980289A
Cited
EP0293181A1
Cited
WO1989001516A1
Cited
WO1989002468A1
Cited
WO1989005349A1
Cited
WO1989005345A1
Cited
WO1989007150A1
Cited
WO1990002806A1
Cited
WO1990005538A1
Cited
WO1990011092A1
Cited
WO1990012087A1
Cited
WO1990015141A2
Cited
WO1991002805A2
Cited
WO1991006658A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-10-05 | 2002-04-06 | 2002-10-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-10-05 | 2006-04-06 | 2006-10-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-10-05 | 2010-04-06 | 2010-10-06 | $7700.00 | Window Closed / Lapsed |